- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01975259
Investigating the Incretin Effect in Cystic Fibrosis (IECF)
Most Cystic fibrosis (CF) patients now commonly live well into adulthood, this means they are progressively accumulating damage to the insulin-secreting cells inside their pancreas. This explains why most adult patients have some degree of abnormal sugar regulation & rates of diabetes rise significantly with age. CF related diabetes is categorically different from other types of diabetes & its development is serious as it heralds a faster decline in lung function & a reduced life expectancy.
The hallmark of abnormal sugar handling in CF is high glucose levels after meals as the damaged pancreas responds abnormally slowly. Over 70% of the initial response of a healthy pancreas is induced, not by glucose alone, but by hormones released from the bowel known as incretins. We want to establish whether incretins are important in blood sugar handling in CF as specific drugs that enhance their effect are now available.
The study hypothesis is that the incretin system will function normally in patients with Cystic Fibrosis. To show this we will measure how much insulin secretion is dependant on incretin hormones in CF patients by comparing levels after a sugary drink test and then an intravenous glucose drip test (run at a rate that mimics the blood sugar levels obtained during the first test to make it a fair comparison ) - as incretins will only be produced in the first test when the sugar passes through the bowel any extra insulin produced will be due to these hormones. To detect resistance to the incretin hormones we will separately measure responses to direct infusions of the hormones themselves. We will explore which components of meals cause incretin hormone release from the bowel wall by measuring blood levels after different types of meals are consumed. Finally we will measure levels of the enzyme that breaks down the incretin hormones (DPP-4) to know if they are deactivated more quickly in people with CF. By describing the incretin system in CF we will considerably improve our understanding of this important condition as well as potentially highlighting new ways to treat it.
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: Oral Glucose Tolerance test (75g 2-hour)
- Drug: Modified Oral Glucose Tolerance Test (50g 4-hours)
- Drug: Matched isoglycemic clamp
- Drug: Hyperglycemic clamp with concurrent GLP-1 infusion
- Drug: Hyperglycemic Clamp with concurrent GIP infusion
- Drug: Hyperglycemic clamp with placebo infusion
- Other: Liquid Meal Test (Carbohydrate-rich)
- Other: Liquid Meal Test (Fat-rich)
- Other: Liquid Meal Test (Mixed)
- Device: Continuous Glucose Monitoring
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Liverpool, United Kingdom, L14 3PE
- Liverpool Heart and Chest Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The CF Cohort will be recruited from the population of Patients attending Adult CF Service at Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
The control group will be invited to participate from the general public. We will advertise our study through the Liverpool Heart & Chest Hospital and also via GP surgeries (Primary care clinics) in both electronic & paper forms.
Description
Inclusion Criteria:
- Cystic fibrosis as diagnosed by EITHER Cystic fibrosis transmembrane conductance regulator (CFTR) mutation on genotyping OR Positive sweat test (Chloride ≥60mmol/L after pilocarpine iontophoresis) AND Clinical features in keeping with a diagnosis of Cystic Fibrosis
- Clinically stable for at least 4 weeks without inpatient or outpatient treatment for an infective exacerbation - including antibiotics (other than long-term prophylactic therapy) or steroids
Exclusion Criteria:
- Active Pregnancy or <12 months Post-partum
- Clinically unstable patients
- Patients on long-term steroids
- Patients with known gastroparesis or previous surgery to the gastrointestinal tract (including vagotomy)
- History of organ transplant or planned organ transplant awaited
- Non-CF related diabetes (e.g. Type 1 or 2 Diabetes Mellitus)
- Active malignancy
- Clinically significant derangements in haematological or biochemical indices
- Clinical symptoms of malabsorption (frequent bowel motions/passing of undigested foodstuffs or steatorrhoea)
- Known difficult venous access
- Use of bile acid sequestrants in the previous 4 weeks
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cystic Fibrosis
Adult patients with confirmed cystic fibrosis who are clinically stable. Interventions: Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich) Continuous Glucose Monitoring |
A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution & have glucose levels recorded up to every 30 mins for 2hours
Other Names:
A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution & have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
Other Names:
A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test.
This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test.
The same blood tests will be performed at the same time points as the modified glucose tolerance test
Other Names:
An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).
After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins.
Subjects will be blinded to what infusion they are receiving.
Other Names:
An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).
After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins.
Subjects will be blinded to what infusion they are receiving.
Other Names:
An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving.
Other Names:
A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs).
Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs).
Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs).
Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days.
The device uses a small plastic tube to record the glucose level from interstitial fluid & every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
Other Names:
|
Controls
Adult Non-CF subjects matched for age and body mass index with normal glucose tolerance. Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich) |
A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution & have glucose levels recorded up to every 30 mins for 2hours
Other Names:
A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution & have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
Other Names:
A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test.
This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test.
The same blood tests will be performed at the same time points as the modified glucose tolerance test
Other Names:
An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).
After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins.
Subjects will be blinded to what infusion they are receiving.
Other Names:
An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).
After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins.
Subjects will be blinded to what infusion they are receiving.
Other Names:
An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving.
Other Names:
A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs).
Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs).
Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs).
Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under Curve (AUC) of Insulin & C-peptide secretion during a matched isoglycemic clamp
Time Frame: 4 hours
|
Differences in Insulin & C-peptide secretion will be measured over a 4-hour period following an oral glucose tolerance test and then separately over the same period during a matched isoglycemic glucose infusion (which will recreate the glucose values obtained during the oral glucose tolerance test).
The difference in these values can be wholly attributed to the effect of incretin hormones.
|
4 hours
|
Volume of intravenous glucose required to maintain a hyperglycemic clamp at 180-216mg/dL
Time Frame: 3 hours
|
A hyperglycemic clamp uses an intravenous glucose infusion to fix blood sugar at a certain level.
We will use such a technique to fix blood sugar levels at 180-216mg/dL (10-12 mmol/l) for one hour then infuse either an incretin hormone (GLP-1/GIP) or placebo (sodium chloride) for a further two hours.
The excess volume of intravenous glucose required during the last two hours of the test (compared to the first) will allow us to calculate what if any effect the incretin hormones have on the pancreas in patients with Cystic Fibrosis
|
3 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum DPP-4 levels
Time Frame: 0 mins
|
We will measure serum DPP-4 levels on 2 separate occasions in both CF and control groups to establish if there are any differences in how rapidly the incretin hormones are deactivated between the groups
|
0 mins
|
AUC incretin hormone levels (GLP-1/GIP)
Time Frame: 4 hours
|
Incretin hormone levels (GLP-1/GIP) will be measured in response to an oral glucose tolerance test, an intravenous isoglycemic glucose infusion as well as in response to standardised meals of different composition (fat-rich, carbohydrate rich & mixed).
|
4 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gareth H Jones, MBChB, Liverpool Heart and Chest Hospital
Publications and helpful links
General Publications
- Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):891-5. doi: 10.1164/ajrccm.162.3.9904075.
- Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986 Jan;29(1):46-52. doi: 10.1007/BF02427280.
- Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993 Jan;91(1):301-7. doi: 10.1172/JCI116186.
- Hameed S, Morton JR, Jaffe A, Field PI, Belessis Y, Yoong T, Katz T, Verge CF. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care. 2010 Feb;33(2):221-6. doi: 10.2337/dc09-1492. Epub 2009 Nov 12.
- Mohan K, Miller H, Dyce P, Grainger R, Hughes R, Vora J, Ledson M, Walshaw M. Mechanisms of glucose intolerance in cystic fibrosis. Diabet Med. 2009 Jun;26(6):582-8. doi: 10.1111/j.1464-5491.2009.02738.x.
- Dobson L, Sheldon CD, Hattersley AT. Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis. Diabetes Care. 2003 Jun;26(6):1940-1. doi: 10.2337/diacare.26.6.1940-a. No abstract available.
- Costa M, Potvin S, Hammana I, Malet A, Berthiaume Y, Jeanneret A, Lavoie A, Levesque R, Perrier J, Poisson D, Karelis AD, Chiasson JL, Rabasa-Lhoret R. Increased glucose excursion in cystic fibrosis and its association with a worse clinical status. J Cyst Fibros. 2007 Nov 30;6(6):376-83. doi: 10.1016/j.jcf.2007.02.005. Epub 2007 Apr 3.
- Hillman M, Eriksson L, Mared L, Helgesson K, Landin-Olsson M. Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. J Cyst Fibros. 2012 Mar;11(2):144-9. doi: 10.1016/j.jcf.2011.11.001. Epub 2011 Dec 3.
- Anzeneder L, Kircher F, Feghelm N, Fischer R, Seissler J. Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis. Horm Metab Res. 2011 May;43(5):355-60. doi: 10.1055/s-0031-1275270. Epub 2011 Mar 29.
- Lanng S, Thorsteinsson B, Roder ME, Orskov C, Holst JJ, Nerup J, Koch C. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinol (Copenh). 1993 Mar;128(3):207-14. doi: 10.1530/acta.0.1280207.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Pancreatic Diseases
- Fibrosis
- Cystic Fibrosis
- Physiological Effects of Drugs
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Incretins
- Glucagon
- Gastric Inhibitory Polypeptide
- Glucagon-Like Peptide 1
Other Study ID Numbers
- 1004
- 2013-003758-26 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
University Hospital, BordeauxCompleted
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
Clinical Trials on Oral Glucose Tolerance test (75g 2-hour)
-
Mednax Center for Research, Education, Quality...Banner University Medical CenterTerminated
-
Clalit Health ServicesUnknownGlucose Tolerance Impaired in Pregnancy
-
Shanghai First Maternity and Infant HospitalCompletedPregnancy | Gestational Diabetes Mellitus | Thyroid Function Tests
-
Hospital Universitario Dr. Jose E. GonzalezCompletedLow Birth Weight | Oral Glucose Tolerance TestMexico
-
University of Alabama at BirminghamUniversity of North Carolina, Chapel HillRecruitingGestational DiabetesUnited States
-
VA Office of Research and DevelopmentKessler FoundationCompleted
-
University Hospital Schleswig-HolsteinUniversity of KielRecruitingParkinson Disease | Nutritional and Metabolic Diseases | Sugar IntakeGermany
-
University College DublinCompletedHealthy SubjectsIreland
-
Université de SherbrookeThe Lawson FoundationCompleted
-
NYU Langone HealthCompletedGlucose Metabolism Disorders | Diabetes Mellitus | Prediabetic State | Diabetes, GestationalUnited States